Program
Dipyrone
Also written as “dipyrone monohydrate 1000 mg + chlorpheniramine maleate 4 mg + caffeine 60 mg”, “dipyrone monohydrate 500 mg + chlorpheniramine maleate 2 mg + caffeine 30 mg” and “Metamizole”.
Its studies are mostly in Nasal Obstruction · Stroke · Migraine Disorders · Fever, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheim | 20 open or running | phase 4since Jul 8, 2014 | Jul 4, 2014 | none ahead |
| Hypera Pharma | 21 open or running | phase 4since May 20, 2011 | May 20, 2011 | Jun 28, 2027phase 3 · NCT07626437 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 20, 2011First study: phase 4 study in FeverNew to Hypera PharmaHypera Pharma · NCT01359020 · 396 enrolled · Brazil
- Jul 4, 2014Boehringer Ingelheim's first study: phase 3 study in Migraine DisordersNew to Boehringer IngelheimBoehringer Ingelheim · NCT02183220 · 417 enrolled
- Jul 8, 2014Phase 4 study in StrokeBoehringer Ingelheim · NCT02184260 · 58 enrolled
- May 19, 2026Phase 3 study in Nasal ObstructionHypera Pharma · NCT07626437 · 620 planned · Brazil
Ahead
- Jun 28, 2027Primary completion: phase 3 study in Nasal ObstructionHypera Pharma · NCT07626437
TargetBeta
“Cyclooxygenase inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Acetaminophenrule | Johnson & Johnson | phase 4 | 136 |
| Ibuprofenrule | Pfizer | phase 4 | 113 |
| Aspirinrule | Bayer | phase 4 | 84 |
| dexketoprofenrule | Menarini Group | phase 4 | 8 |
| Sulfasalazinerule | Bristol-Myers Squibb | phase 4 | 7 |
| dexibuprofenrule | aponia-laboratories-inc | phase 4 | 6 |
| Benzydaminerule | Angelini Pharma | phase 4 | 4 |
| Piroxicamrule | Taisho Pharmaceutical | phase 4 | 4 |
| Flurbiprofenrule | GlaxoSmithKline | phase 3 | 12 |
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07626437Nasal Obstruction · Brazil | 3 | Recruiting | Hypera Pharma | Jun 28, 2027 | 620 |
| NCT02184260Stroke | 4 | Terminated | Boehringer Ingelheim | May 2002 | 58 |
| NCT02183220Migraine Disorders | 3 | Completed | Boehringer Ingelheim | Jul 1999 | 417 |
| NCT01359020Fever · Brazil | 4 | Completed | Hypera Pharma | Mar 2008 | 396 |
How it is read
Names in the registry
- “dipyrone monohydrate 1000 mg + chlorpheniramine maleate 4 mg + caffeine 60 mg”, 1 entry
- “dipyrone monohydrate 500 mg + chlorpheniramine maleate 2 mg + caffeine 30 mg”, 1 entry
- “Metamizole”, 1 entry
- “Metamizol”, 1 entry
- “ibuprofen, dipyrone, acetaminophen”, 1 entry
Conditions, from the studies’ own filings
- Nasal Obstruction, 1 study
- Stroke, 1 study
- Migraine Disorders, 1 study
- Fever, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.